BRPI0818762A8 - Composição farmacêutica bicamada de liberação imediata e controlada contendo tramadol e acetaminofeno, e, uso de uma composição - Google Patents

Composição farmacêutica bicamada de liberação imediata e controlada contendo tramadol e acetaminofeno, e, uso de uma composição

Info

Publication number
BRPI0818762A8
BRPI0818762A8 BRPI0818762A BRPI0818762A BRPI0818762A8 BR PI0818762 A8 BRPI0818762 A8 BR PI0818762A8 BR PI0818762 A BRPI0818762 A BR PI0818762A BR PI0818762 A BRPI0818762 A BR PI0818762A BR PI0818762 A8 BRPI0818762 A8 BR PI0818762A8
Authority
BR
Brazil
Prior art keywords
acetaminophen
composition
buccoat
immediate
controlled release
Prior art date
Application number
BRPI0818762A
Other languages
English (en)
Inventor
Bichara Ali
Gervais Sonia
Le Garrec Dorothée
Ouajdi Patricia
Sant Vinayak
Gosein Shiva
Lemaire Vincent
Taga Samir
Smith Damon
Original Assignee
Labopharm Inc
Paladin Labs Barbados Inc
Chimigen Inc
Paladin Labs Inc
Labopharm Europe Ltd
Paladin Labs Europe Ltd
Labopharm Barbados Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Inc, Paladin Labs Barbados Inc, Chimigen Inc, Paladin Labs Inc, Labopharm Europe Ltd, Paladin Labs Europe Ltd, Labopharm Barbados Ltd filed Critical Labopharm Inc
Publication of BRPI0818762A2 publication Critical patent/BRPI0818762A2/pt
Publication of BRPI0818762A8 publication Critical patent/BRPI0818762A8/pt
Publication of BRPI0818762B1 publication Critical patent/BRPI0818762B1/pt
Publication of BRPI0818762B8 publication Critical patent/BRPI0818762B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIÇÃO DE BICAMADA PARA A LIBERAÇÃO DE TRAMADOL E ACETAMINOFENO, USO DE UMA COMPOSIÇÃO, E, MÉTODO DE TRATAR UM MAMÍFERO EM NECESSIDADE DE ANALGESIA. A invenção diz respeito a uma composição de bicamada para a liberação de acetaminofeno e tramadol em pelo menos um período de doze horas a seguir da administração inicial. Uma única administração da composição de bicamada pode fornecer analgesia iniciando em menos do que meia hora depois da administração inicial com uma duração de pelo menos doze horas depois da administração inicial.
BRPI0818762A 2007-10-16 2008-10-15 composição farmacêutica bicamada de liberação imediata e controlada contendo tramadol e acetaminofeno, e, uso de uma composição BRPI0818762B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98020307P 2007-10-16 2007-10-16
US60/980203 2007-10-16
PCT/CA2008/001799 WO2009049405A1 (en) 2007-10-16 2008-10-15 Bilayer composition for the sustained release of acetaminophen and tramadol

Publications (4)

Publication Number Publication Date
BRPI0818762A2 BRPI0818762A2 (pt) 2015-04-07
BRPI0818762A8 true BRPI0818762A8 (pt) 2017-09-19
BRPI0818762B1 BRPI0818762B1 (pt) 2019-07-02
BRPI0818762B8 BRPI0818762B8 (pt) 2021-05-25

Family

ID=40566952

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818762A BRPI0818762B8 (pt) 2007-10-16 2008-10-15 composição farmacêutica bicamada de liberação imediata e controlada contendo tramadol e acetaminofeno, e, uso de uma composição

Country Status (15)

Country Link
US (1) US8895066B2 (pt)
EP (1) EP2203166B1 (pt)
JP (1) JP5453280B2 (pt)
KR (1) KR20100069685A (pt)
CN (1) CN101827590A (pt)
AR (1) AR068891A1 (pt)
AU (1) AU2008314454A1 (pt)
BR (1) BRPI0818762B8 (pt)
CA (1) CA2678092C (pt)
CO (1) CO6270218A2 (pt)
ES (1) ES2541809T3 (pt)
MX (1) MX336494B (pt)
RU (1) RU2469718C2 (pt)
TW (1) TW200927196A (pt)
WO (1) WO2009049405A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162431A1 (en) * 2002-09-21 2009-06-25 Shuyi Zhang Sustained release formulations containing acetaminophen and tramadol
CA2720108C (en) 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20120015031A1 (en) 2010-07-14 2012-01-19 Grunenthal Gmbh Novel gastro-retentive dosage forms
CN102670542A (zh) * 2011-03-17 2012-09-19 北京天衡药物研究院 ***马多渗透泵控释片
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
EP2968182B8 (en) * 2013-03-15 2018-07-25 SpecGx LLC Abuse deterrent solid dosage form for immediate release with functional score
DE102013009114A1 (de) 2013-05-29 2014-12-04 Franz Gerstheimer Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
KR101710792B1 (ko) * 2015-07-14 2017-02-28 주식회사 유영제약 세레콕시브 및 트라마돌을 함유하는 약제학적 조성물
US9693949B1 (en) * 2015-12-22 2017-07-04 Revogenex Ireland Ltd Intravenous administration of tramadol
US9980900B2 (en) * 2015-12-22 2018-05-29 Revogenex Ireland Ltd Intravenous administration of tramadol
EP3694557B1 (en) * 2017-10-13 2022-04-13 Altus Formulation Inc. Starch-based release modifying excipients and pharmaceutical compositions derived therefrom
GB2567493B (en) * 2017-10-13 2019-12-18 Altus Formulation Inc Starch-based release modifying excipients and pharmaceutical compositions derived therefrom
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
DE102021210130A1 (de) * 2021-09-14 2023-03-16 Robert Bosch Gesellschaft mit beschränkter Haftung Fluidleitvorrichtung für einen Scheibenwischer
WO2024144258A1 (ko) * 2022-12-28 2024-07-04 주식회사 삼양홀딩스 룩소리티닙의 다중 방출제어 정제 조성물 및 이의 제조 방법

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US4968509A (en) * 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
CA2041774C (en) * 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
ES2120451T7 (es) * 1991-09-06 2009-11-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Composicion que comprende un compuesto de tramadol y acetaminofeno, y su uso.
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
GB9519363D0 (en) * 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US5807575A (en) * 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6156342A (en) * 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
IT1301966B1 (it) * 1998-07-30 2000-07-20 Zambon Spa Composizioni farmaceutiche ad attivita' analgesica
US6245387B1 (en) * 1998-11-03 2001-06-12 Diamon-Fusion International, Inc. Capped silicone film and method of manufacture thereof
CA2371940C (en) * 1999-03-31 2008-07-15 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
JP2004513091A (ja) * 2000-10-03 2004-04-30 ペンウェスト　ファーマシューティカルズ　カンパニー 異なる速度の複数の医薬活性成分の送達系
US20020106408A1 (en) * 2000-12-01 2002-08-08 Johnatan Bacon Prolamin-based sustained-release compositions and delayed-onset compositions
US6968551B2 (en) * 2001-06-11 2005-11-22 John Hediger System and user interface for generation and processing of software application installation instructions
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
KR100522239B1 (ko) 2002-07-16 2005-10-18 주식회사 서울제약 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
EP1555022B1 (en) * 2002-09-21 2008-02-20 Shuyi Zhang Sustained release formulation of acetaminophen and tramadol
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
RU2333745C2 (ru) * 2002-10-25 2008-09-20 Лабофарм Инк. Композиции с контролируемым высвобождением
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
CA2419349A1 (en) * 2003-02-20 2004-08-20 Geoffrey Lambert A modular display holder for a card
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
NZ546148A (en) * 2003-09-26 2009-05-31 Alza Corp Drug coating providing high drug loading and methods for providing the same
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050157382A1 (en) * 2004-01-07 2005-07-21 Kafka James D. Industrial directly diode-pumped ultrafast amplifier system
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20060257473A1 (en) * 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
ES2441766T3 (es) * 2005-08-24 2014-02-06 Endo Pharmaceuticals Inc. Formulaciones de nalbufina de liberación sostenida
ES2389666T3 (es) * 2005-09-09 2012-10-30 Angelini Labopharm, Llc Composición de trazodona para una administración de una vez al día
EA020867B1 (ru) * 2006-03-06 2015-02-27 Поузен Инк. Лекарственные формы для введения комбинаций лекарственных средств
US20070237816A1 (en) * 2006-04-06 2007-10-11 David Finkelstein Acetaminophen formulation for joint pain relief

Also Published As

Publication number Publication date
BRPI0818762B1 (pt) 2019-07-02
AU2008314454A1 (en) 2009-04-23
CA2678092C (en) 2013-07-30
WO2009049405A1 (en) 2009-04-23
MX336494B (es) 2016-01-21
CN101827590A (zh) 2010-09-08
ES2541809T3 (es) 2015-07-24
KR20100069685A (ko) 2010-06-24
JP2011500607A (ja) 2011-01-06
RU2010119463A (ru) 2011-11-27
MX2010004236A (es) 2010-09-07
US20090130183A1 (en) 2009-05-21
AR068891A1 (es) 2009-12-16
EP2203166A4 (en) 2012-07-04
JP5453280B2 (ja) 2014-03-26
BRPI0818762A2 (pt) 2015-04-07
US8895066B2 (en) 2014-11-25
BRPI0818762B8 (pt) 2021-05-25
EP2203166B1 (en) 2015-05-06
RU2469718C2 (ru) 2012-12-20
TW200927196A (en) 2009-07-01
CO6270218A2 (es) 2011-04-20
EP2203166A1 (en) 2010-07-07
CA2678092A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
BRPI0818762A8 (pt) Composição farmacêutica bicamada de liberação imediata e controlada contendo tramadol e acetaminofeno, e, uso de uma composição
CL2011000501A1 (es) Composición farmacéutica que comprende un agonista de gpr119 en combinación con un inhibidor de dpp-4 seleccionado de un grupo definido; uso para prevenir y/o tratar enfermedades metabólicas, como resistencia insulinica, diabetes, sindrome metabolico, obesidad, hiperlipidemia, osteoporosis, entre otras.
AR061967A1 (es) Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metil-piridin-3-il-amino)-5-metil-pirimidin-4-iloxi]-piperidin-i-carboxilico, composicion farmaceutica que lo comprende y un metodo de preparacion de la misma y el uso de este compuesto para el tratamiento de trastornos metabolicos
MX360289B (es) Composiciones de tapentadol.
CL2011000851A1 (es) Composicion farmaceutica que comprende al menos una insulina y al menos un agonista de glp-1; metodo de preparacion; su uso para tratar diabetes o prevenir la disfuncion de celulas beta pancreaticas; kit; y dispositivo.
AR061968A1 (es) Ester isopropilico del acido 4-[5-metoxi-6-(2-metil-6-[1,2,4]triazol-i-il-piridin-3-il-amino)-pirimidin-4-iloxi]-piperidin-i-carboxilico, composicion farmaceutica que lo comprende y un metodo de preparacion de la misma y el uso de este compuesto para el tratamiento de trastornos metabolicos
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
CL2010001526A1 (es) Compuestos derivados de isonicotinamida, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que comprende un compuesto;utiles para tratar enfermedades relacionadas con dislipidemia y trastornos del metabolismo de lipidos.
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
CR11849A (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad
BR122019021238B8 (pt) uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
CL2008002999A1 (es) Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon.
NO20090605L (no) Metode for inhibering av respirasjonsdepresjon ved bruk av positive allosteriske AMPA reseptormodulatorer
BR112013001299A2 (pt) composições farmacêuticas e respectivo uso e métodos de tratamento de diabetes e doenças correlatas em paciente humano
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
NO20080936L (no) Transdermale medikamentleveringsinnretninger inneholdende O-desmetylvenlafaksin (ODV) eller salter derav
AR053928A1 (es) Metodos reactivos para el tratamiento de trastornos inflamatorios
BRPI0810773A2 (pt) Composição farmacêutica, métodos para tratar dor em um mamífero, para tratar depressão em um mamífero, para tratar um distúrbio em um paciente, para fabricar um composto, e para inibir a captação de norepinefrina, composto, e, uso de uma composição.
BRPI0519006A2 (pt) uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
CL2008002289A1 (es) Compuestos derivados de n-heteroaril-carboxamidas triciclicas; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar dolor, inflamacion, trastornos metabolicos, trastornos urologicos, entre otros.
BRPI0922439A2 (pt) composto, composição farmacêutica, uso de um composto, e , método para a terapia da dor em uma animal de sangue quente.
AR067351A1 (es) Combinacion de picotamida con nafronil
AR048460A1 (es) Tratamiento de la funcion respiratoria alterada con gaboxadol
BRPI0721333A8 (pt) Composição útil para o tratamento de diabetes tipo 2

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADO

B25D Requested change of name of applicant approved

Owner name: LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADOS) LIMITED (BB) , LABOPHARM INC. (CA)

Owner name: LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADO

B25A Requested transfer of rights approved

Owner name: LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADO

B25D Requested change of name of applicant approved

Owner name: LABOPHARM (BARBADOS) LIMITED (BB) , PALADIN LABS I

B25G Requested change of headquarter approved

Owner name: PALADIN LABS INC. (CA) , PALADIN LABS EUROPE LIMIT

B25A Requested transfer of rights approved

Owner name: PALADIN LABS INC. (CA) , PALADIN LABS EUROPE LIMIT

B25D Requested change of name of applicant approved

Owner name: PALADIN LABS INC. (CA) , PALADIN LABS EUROPE LIMIT

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed